NeoStem (NYSE:NBS) said Friday that it will present at two upcoming conferences this month, where it will give corporate updates.
The company, founded in 1980 and with about 611 employees, develops
cellular therapies for oncology, immunology and regenerative medicines
in China and the United States.
The first symposium, Cowen and Company’s 32nd Annual Health Care
Conference, is slated to take place on March 5, at 2:50 p.m. at the
Marriott Copley Place, in Boston.
Cowen and Company's symposiums are major industry events attracting
top institutional investors and companies in the technology, health
care, consumer and retail, aerospace and defence and alternative energy
Meanwhile, the second conference – Maxim Group’s 5th Annual Growth
Conference – will take place on March 26 at 9 a.m. at the Grand Hyatt,
in New York.
The second conference is a one-day event that will feature more than
80 presentations across the health care, media and specialty finance
Earlier this week, JMP Securities reiterated its market outperform rating and $3 price target for NeoStem, after Baxter International (NYSE:BAX) named the stem cell company's Progenitor Cell Therapy unit as the contract manufacturer for a phase three stem cell trial.
On Tuesday, Baxter started a phase three, 450 patient pivotal
clinical trial to evaluate the efficacy and safety of an individual's
own CD34+ stem cells to increase exercise capacity in patients with
chronic myocardial ischemia (CMI), a coronary artery disease.
is an international biopharmaceutical company with adult stem cell
operations in the U.S., a network of adult stem cell therapeutic
providers in China as well as a 51 percent ownership interest in a
profitable Chinese generic pharmaceutical manufacturing company.
It is focused on accelerating the development of proprietary cellular
therapies and becoming a single source for collection, storage,
manufacturing, therapeutic development and transportation of cells for
cell-based medicine and regenerative science globally.